CompletedPhase 1ACTRN12612000915853

Evaluation of a novel multi-purpose contact lens solution

A prospective, bilateral, cross-over study to evaluate the safety and subjective acceptance of a novel contact lens multipurpose disinfecting solution and compare with a commercial solution during 1 month contact lens daily wear on experienced lens wearers


Sponsor

Brien Holden Vision Institute

Enrollment

30 participants

Start Date

Nov 13, 2012

Study Type

Interventional

Conditions

Summary

This trial will examine the effect of a novel multipurpose contact lens solution on subjective response and the ocular surface. The hypotheses are these outcomes will be similar for control solutions.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria7

  • Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.
  • Be at least 18 years old, male or female.
  • Be experienced at wearing contact lenses.
  • Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
  • Have ocular health findings considered to be “normal” and which would not prevent the participant from safely wearing contact lenses.
  • Correctable to at least 6/12 or better in each eye with contact lenses.
  • Be willing to not wear contact lenses for at least 2 days before each stage of the clinical trial.

Exclusion Criteria11

  • Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses.
  • Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
  • Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
  • Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.
  • NB: Systemic antihistamines are allowed on an “as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
  • Eye surgery within 12 weeks immediately prior to enrolment for this trial.
  • Previous corneal refractive surgery.
  • Contraindications to contact lens wear.
  • Known allergy or intolerance to ingredients in any of the clinical trial products.Currently enrolled in another clinical trial.
  • Participation in a clinical trial within the previous 2 weeks for dispensing studies and 2 days between in-house studies.
  • Pregnancy* (Formal testing of pregnancy is not required. A participant’s verbal report is sufficient)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This is a prospective, randomised (solution allocation), bilateral, cross-over clinical trial where a minimum of 30 experienced contact lens wearers will use a commercial multipurpose solution (MPS) (

This is a prospective, randomised (solution allocation), bilateral, cross-over clinical trial where a minimum of 30 experienced contact lens wearers will use a commercial multipurpose solution (MPS) (OPTI-FREE (Registered Trademark) Puremoist (Registered Trademark)) (OFPM) and a novel MPS (BHVI7) in conjunction with Clariti (Trademark) and or ACUVUE (Registered Trademark) OASYS (Trademark) contact lenses on a daily wear basis for approximately two or four months. There will be 2 or 4 stages in this study, with each stage corresponding to using one of the MPS for one month. There will be 8 or 16 scheduled visits, with 4 visits per stage: baseline/dispensing visit, 2 hour post insertion, 2 weeks and 1-month visits. These visits will involve assessment of visual acuity, assessment of ocular comfort using questionnaires employing a 1-10 numeric rating scale and ocular response by examination with a slit-lamp biomicroscope (a specialised microscope for viewing the eye). Lenses will be worn a minimum of 5 days per week, 6 hours per day. All solutions will be used after lens removal and as per manufacturer’s recommendation: Rub lenses with solution (5 seconds), rinse lenses with solution (5seconds) and store in solution for at least 6 hours. Solution is not to be reused. Clariti contact lenses will be replaced monthly and ACUVUE OASYS 2-weekly. There will be a 48 hour wash-out where no contact lenses are worn before the commencement of each stage.


Locations(1)

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12612000915853